Oral and Rectal Vancomycin for C. difficile Infection
Rectal vancomycin enema should be added to oral vancomycin (plus IV metronidazole) specifically for fulminant C. difficile infection when ileus is present, not for routine or severe cases. 1
Treatment Algorithm by Disease Severity
Non-Severe and Severe CDI (Without Fulminant Features)
- Use oral vancomycin 125 mg four times daily for 10 days ONLY 1, 2
- Do NOT add rectal vancomycin for these cases
- Oral vancomycin alone achieves 80-81% clinical success rates 2
- Median time to diarrhea resolution: 4-5 days 2
Fulminant CDI (Hypotension/Shock, Ileus, or Megacolon)
This is the ONLY indication for rectal vancomycin:
Triple therapy approach:
- Oral vancomycin 500 mg four times daily (or via nasogastric tube) 1
- IV metronidazole 500 mg every 8 hours 1
- Rectal vancomycin instillation - add specifically if ileus is present 1
Rectal Vancomycin Dosing Specifications
When ileus prevents oral medication from reaching the colon, the evidence supports:
- Dose: 500 mg vancomycin in 500 mL volume every 6 hours 3
- Administration: Retention enema using 18F Foley catheter with 30-cc balloon, inflated in rectum, clamped for 60 minutes 3
- Lower doses (125-250 mg in 100 mL) showed no efficacy in case series 3
Critical Caveat on Rectal Vancomycin Evidence
The evidence for rectal vancomycin is weak. A case-control study of 24 ICU patients showed no reduction in colectomy rates (16.7% vs 16.7%) or mortality (45.8% vs 41.7%) when vancomycin enemas were added to standard therapy 4. However, the guideline recommendation persists based on theoretical benefit when oral delivery is compromised by ileus 1.
Special Situations Requiring Rectal Administration
Rectal vancomycin may be considered when oral administration cannot reach the colon:
- Hartmann's pouch
- Ileostomies
- Colon diversions 5
What NOT to Do
Do not use high-dose oral vancomycin (>500 mg/day) for severe CDI without fulminant features - no evidence supports this practice 5. The standard 125 mg four times daily is equally effective and FDA-approved 2.
Do not use rectal vancomycin as routine adjunctive therapy - it is reserved exclusively for fulminant disease with ileus 1.
Monitoring Considerations
In patients with inflammatory bowel disease, renal insufficiency, or receiving concomitant aminoglycosides, oral vancomycin can achieve measurable serum concentrations 2. Monitor serum vancomycin levels in these high-risk patients, particularly those >65 years due to nephrotoxicity risk 2.
Recurrence Risk
Even with appropriate treatment, CDI recurs in 18-25% of patients within 4 weeks after successful initial treatment 2. This is expected and should prompt consideration of fidaxomicin, tapered vancomycin regimens, or bezlotoxumab for subsequent episodes 1.